Tshekedi Dennis, MD
Psychiatry · Huntington Beach, CANPI 1215015508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 924 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,736, 3.8 times the $1,502 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 924 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Neurocrine Biosciences, Inc.$3K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $7K from 23 others
Across 44 payments — averaging $6182.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$170K
- Biohaven Pharmaceutical Holding Company Ltd.$66K
- Janssen Research & Development, LLC$29K
- Boehringer Ingelheim RCV GmbH & Co KG$7K
What the payments were for
- Food & beverage$22,88899%
- Education$3121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 133 | $4,385 |
| Neurocrine Biosciences, Inc. | 135 | $3,242 |
| AbbVie(2 entities) | 101 | $2,534 |
| Teva Pharmaceuticals USA, Inc. | 112 | $2,432 |
| Alkermes, Inc. | 53 | $1,794 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,767 |
| Vanda Pharmaceuticals Inc. | 68 | $1,463 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,038 |
| Luye Pharma (USA) Ltd. | 33 | $674 |
| Lundbeck LLC | 35 | $658 |
| Indivior Inc. | 37 | $637 |
| Axsome Therapeutics, Inc. | 18 | $518 |
| E.r. Squibb & Sons, L.L.C. | 17 | $470 |
| Sunovion Pharmaceuticals Inc. | 19 | $283 |
| Bausch Health US, LLC | 13 | $272 |
| Boehringer Ingelheim | 2 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $191 |
| Livanova USA, Inc. | 8 | $163 |
| Corium, LLC | 5 | $107 |
| Noven Therapeutics, LLC | 4 | $76 |
| Noven Pharmaceuticals, Inc. | 2 | $67 |
| Almatica Pharma LLC | 2 | $49 |
| Adlon Therapeutics L.p. | 3 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $35 |
| Eisai Inc. | 2 | $31 |
| Novo Nordisk | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,281
- VRAYLAR$993
- REXULTI$829
- ARISTADA$500
- INGREZZA$399
- Fanapt$374
- INVEGA SUSTENNA$350
- INVEGA TRINZA$350
- SPRAVATO$350
- ARISTADA INITIO$125
- Austedo XR$125
- UZEDY$125
- CAPLYTA$125
- ERZOFRI EXTENDED-RELEASE$124
- COBENFY$120
- Auvelity$120
- AUSTEDO$120
How this compares
$23,200 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 133 | $432,623 |
| IngrezzaValbenazine Tosylate | 16 | $126,839 |
| Abilify MaintenaAripiprazole | 35 | $92,982 |
| Clozapine OdtClozapine | 214 | $83,084 |
| AustedoDeutetrabenazine | 11 | $79,414 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $23,257 |
| Olanzapine OdtOlanzapine | 166 | $18,265 |
| Aripiprazole | 153 | $17,067 |
| Divalproex Sodium ErDivalproex Sodium | 208 | $16,176 |
| Quetiapine Fumarate | 238 | $4,542 |
| Divalproex Sodium | 127 | $4,379 |
| Ziprasidone Hcl | 60 | $3,836 |
| Benztropine Mesylate | 227 | $3,591 |
| Haloperidol | 68 | $3,272 |
| Chlorpromazine Hcl | 23 | $3,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $4,385 | $432,623133 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $3,242 | $126,83916 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,767 | $92,98235 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,432 | $79,41411 claims |
| Alkermes, Inc.Lybalvi | $1,794 | $23,25715 claims |
| Almatica Pharma LLCSertraline Hcl | $49 | $67692 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Huntington Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.